Download PDF
Exp Clin Endocrinol Diabetes 2018; 126(05): 268-276
DOI: 10.1055/s-0043-113453
Article
© Georg Thieme Verlag KG Stuttgart · New York

Switching from Premixed Insulin To Basal Insulin Analogue For Type 2 Diabetes and Role of Dipeptidyl Peptidase-4 Inhibitors

Fernando Gómez-Peralta
1   Unit of Endocrinology and Nutrition, Hospital General de Segovia, Miguel Servet, S/N, Segovia, Spain
,
Cristina Abreu
1   Unit of Endocrinology and Nutrition, Hospital General de Segovia, Miguel Servet, S/N, Segovia, Spain
,
Gustavo Mora-Navarro
2   Department of General Medicine, Centro de Salud Los Alpes, Calle Suecia, Madrid, Spain
,
Pilar López-Morandeira
3   Department of General Medicine, Centro de Salud Aquitania, Calle Aquitania, Madrid, Spain
,
Esteban Pérez-Gutierrez
4   Department of General Medicine, Centro de Salud María Jesús Hereza, Calle Jesús Miguel Haddad Blanco, Leganés, Spain
,
Blanca Cordero-García
5   Department of General Medicine, Centro de Salud Santa María Benquerencia, Calle Río Alberche, S/N, 45007 Toledo, Spain
,
Miguel Brito-Sanfiel
6   Unit of Endocrinology and Nutrition, Hospital Universitario Puerta de Hierro Majadahonda, Calle Manuel de Falla, Majadahonda, Spain
› Author Affiliations
Further Information

Publication History

received 16 February 2017
revised 07 June 2017

accepted 12 June 2017

Publication Date:
13 July 2017 (online)

Also available at
    Permissions and Reprints

Abstract

Introduction This study aimed to confirm the usefulness of basal insulin analogue plus oral antidiabetic drugs (OADs) for type 2 diabetes (T2D) patients inadequately controlled with premixed insulin with/without OADs and assess the role of dipeptidyl peptidase-4 (DPP-4) inhibitors within this regimen in clinical practice.

Methods Spanish retrospective observational study that included 186 T2D patients with glycosylated hemoglobin (HbA1c) >7% (53 mmol/mol) despite premixed insulin with/without OADs who had been switched to basal insulin analogue plus OADs. Study data describing the situation before the treatment switch and 6 months later was retrospectively retrieved from patients’ medical charts.

Results Switching to a basal insulin plus OADs decreased HbA1c (−1.0%, p<0.001), fasting (−38.1 mg/dl, p<0.001) and postprandial glycemia (−36.1 mg/dl, p<0.001), with reduced body weight (−1.1 kg, p<0.001) and hypoglycemic episodes (−17.5%, p<0.001). 68 (36.6%) patients received a basal insulin plus DPP-4 inhibitor±metformin and 74 (39.8%) plus metformin only. The DPP-4 inhibitor±metformin group showed a greater HbA1c reduction than the metformin group (1.3±1.4% vs. 0.9±1.0%, p=0.022), with no significant differences between groups in hypoglycemic episodes.

Conclusions Basal insulin analogue plus OADs may be a useful treatment for type 2 diabetes patients inadequately controlled with premixed insulin. Administering DPP-4 inhibitors within this regimen may contribute to improve patients’ glycemia, with a favorable weight-change profile and without increasing hypoglycemia risk.

Key words

antidiabetic drugs - basal insulin - dipeptidyl peptidase-4 inhibitors - premixed insulin - type 2 diabetes mellitus
 

  • References

  • 1 Giugliano D, Maiorino MI, Bellastella G. et al. Treatment regimens with insulin analogues and haemoglobin A1c target of <7% in type 2 diabetes: A systematic review. Diabetes Res Clin Pract 2011; 92: 1-10
    CrossrefPubMedGoogle Scholar
  • 2 Pontiroli AE, Miele L, Morabito A. Metabolic control and risk of hypoglycaemia during the first year of intensive insulin treatment in type 2 diabetes: Systematic review and meta-analysis. Diabetes Obes Metab 2012; 14: 433-446
    CrossrefPubMedGoogle Scholar
  • 3 Qayyum R, Bolen S, Maruthur N. et al. Systematic review: Comparative effectiveness and safety of premixed insulin analogues in type 2 diabetes. Ann Intern Med 2008; 149: 549-559
    CrossrefPubMedGoogle Scholar
  • 4 Qayyum R, Greene L. AHRQ's comparative effectiveness research on premixed insulin analogues for adults with type 2 diabetes: Understanding and applying the systematic review findings. J Manag Care Pharm 2011; 17: S3-19
    PubMedGoogle Scholar
  • 5 Zhang Y, Xie YJ, Meng DD. et al. Clinical study of treatment switching from premixed insulin to basal insulin combined with oral hypoglycemic drugs in patients with type 2 diabetes. Diabetol Metab Syndr 2014; 6: 37
    CrossrefPubMedGoogle Scholar
  • 6 Hammer H, Klinge A. Patients with type 2 diabetes inadequately controlled on premixed insulin: effect of initiating insulin glargine plus oral antidiabetic agents on glycaemic control in daily practice. Int J Clin Pract 2007; 61: 2009-2018
    CrossrefPubMedGoogle Scholar
  • 7 Gomez-Peralta F, Carraminana-Barrera F, Felix-Redondo FJ. et al. Glycaemic control in patients with type 2 diabetes switching from premixed insulin to long-acting basal insulin analogue plus oral antidiabetic drugs: An observational study. Int J Clin Pract 2012; 66: 959-968
    CrossrefPubMedGoogle Scholar
  • 8 American Diabetes Association . Standards of medical care in diabetes-2014. Diabetes Care 2014; 37 (Suppl. 01) S14-S80
    CrossrefPubMedGoogle Scholar
  • 9 Inzucchi SE, Bergenstal RM, Buse JB. et al. Management of hyperglycemia in type 2 diabetes: A patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364-1379
    CrossrefPubMedGoogle Scholar
  • 10 Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: Systematic review and meta-analysis. JAMA 2007; 298: 194-206
    CrossrefPubMedGoogle Scholar
  • 11 Richter B, Bandeira-Echtler E, Bergerhoff K. et al. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2008; CD006739
    PubMedGoogle Scholar
  • 12 Bennett WL, Maruthur NM, Singh S. et al. Comparative effectiveness and safety of medications for type 2 diabetes: An update including new drugs and 2-drug combinations. Ann Intern Med 2011; 154: 602-613
    CrossrefPubMedGoogle Scholar
  • 13 Fonseca V, Schweizer A, Albrecht D. et al. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 2007; 50: 1148-1155
    CrossrefPubMedGoogle Scholar
  • 14 Fonseca V, Baron M, Shao Q. et al. Sustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitus. Horm Metab Res 2008; 40: 427-430
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Rosenstock J, Rendell MS, Gross JL. et al. Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia. Diabetes Obes Metab 2009; 11: 1145-1152
    CrossrefPubMedGoogle Scholar
  • 16 Vilsboll T, Rosenstock J, Yki-Jarvinen H. et al. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes Obes Metab 2010; 12: 167-177
    CrossrefPubMedGoogle Scholar
  • 17 Barnett AH, Charbonnel B, Donovan M. et al. Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin. Curr Med Res Opin 2012; 28: 513-523
    CrossrefPubMedGoogle Scholar
  • 18 Hong ES, Khang AR, Yoon JW. et al. Comparison between sitagliptin as add-on therapy to insulin and insulin dose-increase therapy in uncontrolled Korean type 2 diabetes: CSI study. Diabetes Obes Metab 2012; 14: 795-802
    CrossrefPubMedGoogle Scholar
  • 19 Bradley C. Diabetes treatment satisfaction questionnaire. Change version for use alongside status version provides appropriate solution where ceiling effects occur. Diabetes Care 1999; 22: 530-532
    CrossrefPubMedGoogle Scholar
  • 20 Gomis R, Herrera-Pombo JL, Calderón A. et al. Validación del cuestionario "Diabetes treatment satisfaction questionnaire" (DTSQ) en la población española. Parmacoeconomics – Spanish Research Articles 2006; 3: 7-18
    PubMedGoogle Scholar
  • 21 Yki-Jarvinen H, Kauppinen-Makelin R, Tiikkainen M. et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia 2006; 49: 442-451
    CrossrefPubMedGoogle Scholar
  • 22 Fonseca V, Gill J, Zhou R. et al. An analysis of early insulin glargine added to metformin with or without sulfonylurea: Impact on glycaemic control and hypoglycaemia. Diabetes Obes Metab 2011; 13: 814-822
    CrossrefPubMedGoogle Scholar
  • 23 Meneghini L, Kesavadev J, Demissie M. et al. Once-daily initiation of basal insulin as add-on to metformin: A 26-week, randomized, treat-to-target trial comparing insulin detemir with insulin glargine in patients with type 2 diabetes. Diabetes Obes Metab 2013; 15: 729-736
    CrossrefPubMedGoogle Scholar
  • 24 Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26: 3080-3086
    CrossrefPubMedGoogle Scholar
  • 25 Ferrannini E, Fonseca V, Zinman B. et al. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab 2009; 11: 157-166
    CrossrefPubMedGoogle Scholar
  • 26 Nauck MA, Meininger G, Sheng D. et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: A randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007; 9: 194-205
    CrossrefPubMedGoogle Scholar
  • 27 Phung OJ, Scholle JM, Talwar M. et al. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA 2010; 303: 1410-1418
    CrossrefPubMedGoogle Scholar
  • 28 Omar BA, Liehua L, Yamada Y. et al. Dipeptidyl peptidase 4 (DPP-4) is expressed in mouse and human islets and its activity is decreased in human islets from individuals with type 2 diabetes. Diabetologia 2014; 57: 1876-1883
    CrossrefPubMedGoogle Scholar
  • 29 Herman GA, Bergman A, Stevens C. et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 2006; 91: 4612-4619
    CrossrefPubMedGoogle Scholar
  • 30 Ahren B, Landin-Olsson M, Jansson PA. et al. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 2004; 89: 2078-2084
    CrossrefPubMedGoogle Scholar